Century Therapeutics (IPSC) TD Cowen 46th Annual Health Care Conference summary

Strategic priorities and program focus

• Advancing two main programs: CNTY-813 for Type 1 Diabetes and CNTY-308 for B-cell-mediated autoimmune diseases, both featuring advanced Allo-Evasion 5.0 technology.

• IND submission for CNTY-813 targeted for late 2024, with clinical entry and initial data generation as key 12–24 month goals.

• CNTY-308 aims to enter the clinic in 2024, leveraging iPSC-derived T cells with immune evasion to potentially reduce or eliminate lymphodepletion.

• Long-term vision includes expanding iPSC-derived therapies to additional diseases and leveraging internal capabilities in developmental biology and manufacturing.

Technology platform and differentiation

• iPSC-derived cells offer unlimited scalability and the ability to generate any adult cell type, supporting broad therapeutic applications.

• Allo-Evasion 5.0 removes HLA Class I/II, adds a universal NK inhibitory ligand (CD300a TASR), and expresses an IgG-degrading protease for comprehensive immune protection.

• Preclinical data show superior protection against NK and IgG-mediated rejection compared to other technologies.

• Allo-Evasion 5.0 is positioned as best-in-class for immune evasion, with broad applicability across cell types.

CNTY-813 (Type 1 Diabetes) program details

• Addresses significant unmet need: 10 million global T1D patients, many experiencing severe hypoglycemic events and long-term complications despite insulin therapy.

• Cadaveric islet transplant data support the approach but are limited by need for chronic immunosuppression.

• Preclinical studies confirm iPSC-derived beta islet cells match gene expression and function of native islets, restoring normoglycemia in diabetic animal models.

• IND-enabling studies are progressing, with positive FDA feedback and focus on tumorigenicity and toxicity studies.

• Early clinical trials will assess safety, engraftment, insulin independence, and reduction of immunosuppression, with pivotal data expected by 2027 and potential commercialization in early 2030s.